The CEO of the French company Apyvax, Marc de Garidel, announced that the company is not in a rush to sell itself, as it plans to raise funds following the release of critical trial data in June. These statements come at a time when the company is facing strong rumors about a potential acquisition by major pharmaceutical companies, which has impacted its stock price, witnessing a staggering increase of up to 1700% in 2025.
Apyvax is preparing to release results from an advanced trial assessing the long-term effects of its lead treatment, Opfazimod, in the second quarter of the year. If the results are positive, the company plans to submit a request for approval from the U.S. Food and Drug Administration in the last quarter of the year.
Details of the Event
Opfazimod is considered a potential first-line treatment for ulcerative colitis and is also being tested as a treatment for Crohn's disease, opening up a massive market estimated in billions of dollars for treating irritable bowel syndrome. De Garidel explained that waiting until after the trial results would be more logical, as the conditions would be better if the results are positive.
De Garidel stated, "Why rush? We are three months away from getting the results," noting that investors view these results as a key turning point for the company, and potential buyers are closely monitoring the situation.
Background & Context
Apyvax was founded in 2013 and has focused on developing new treatments for inflammatory diseases. The company has seen significant growth in recent years, making it an attractive target for acquisition by major pharmaceutical companies. In July of last year, Apyvax managed to raise nearly $750 million after a clinical trial that led to a 510% increase in its stock price in one day.
Biotech companies approaching market launches need to prepare to go solo, but the general assumption is that they will be acquired before obtaining approval or launching. Analysts indicate that positive results from the maintenance trial have already been priced into the company's stock.
Impact & Consequences
Apyvax expects to raise funds through a potential mix of equity and debt financing after obtaining trial data. De Garidel confirmed that the company has enough liquidity to cover its needs until the end of 2027, reporting a cash reserve of €530 million ($613 million) at the end of 2025.
Apyvax faces significant challenges if it decides to seek an external partner, as the drug pricing policy implemented by former President Donald Trump may complicate matters, requiring the company to ensure that any external partner does not negatively affect operations in the United States.
Regional Significance
The developments in pharmaceuticals and new treatments are particularly important for the Arab region, where many countries suffer from high rates of chronic diseases such as ulcerative colitis and Crohn's disease. If Apyvax succeeds in developing an effective treatment, it could open new horizons for patients in the region and enhance opportunities for collaboration between Arab companies and global firms.
In conclusion, Apyvax appears to be adopting a thoughtful strategy in dealing with acquisition rumors, reflecting its confidence in the upcoming trial results and its ability to attract the right partners in the future.